Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 2/6 |
Financial Health | 3/6 |
Dividends | 0/6 |
524202 Stock Overview
Lactose (India) Limited manufactures and trades in pharmaceutical products in India.
Lactose (India) Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | ₹89.55 |
52 Week High | ₹96.35 |
52 Week Low | ₹33.10 |
Beta | -0.12 |
1 Month Change | 20.93% |
3 Month Change | 27.84% |
1 Year Change | 142.68% |
3 Year Change | 281.06% |
5 Year Change | -43.52% |
Change since IPO | 15,610.53% |
Recent News & Updates
Shareholder Returns
524202 | IN Pharmaceuticals | IN Market | |
---|---|---|---|
7D | 12.1% | 0.5% | 1.0% |
1Y | 142.7% | -14.2% | 8.0% |
Return vs Industry: 524202 exceeded the Indian Pharmaceuticals industry which returned -14.2% over the past year.
Return vs Market: 524202 exceeded the Indian Market which returned 8% over the past year.
Price Volatility
524202 volatility | |
---|---|
524202 Average Weekly Movement | 7.7% |
Pharmaceuticals Industry Average Movement | 5.9% |
Market Average Movement | 6.6% |
10% most volatile stocks in IN Market | 9.2% |
10% least volatile stocks in IN Market | 4.3% |
Stable Share Price: 524202 is not significantly more volatile than the rest of Indian stocks over the past 3 months, typically moving +/- 8% a week.
Volatility Over Time: 524202's weekly volatility (8%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1991 | 103 | Atul Maheshwari | https://www.lactoseindialimited.com |
Lactose (India) Limited manufactures and trades in pharmaceutical products in India. The company offers lactose monohydrate; dry granulated, film, and lacquer coated tablets; and pharmaceutical products in liquid dose forms. It also provides disaccharide lactulose, an active pharmaceutical ingredient that is used in the treatment of constipation, hepatitis encephalopathy, intestinal microflora, dental care, diabetes, and chronic liver disease, as well as for use as a prebiotic.
Lactose (India) Fundamentals Summary
524202 fundamental statistics | |
---|---|
Market Cap | ₹1.13b |
Earnings (TTM) | ₹24.51m |
Revenue (TTM) | ₹459.39m |
46.0x
P/E Ratio2.5x
P/S RatioIs 524202 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
524202 income statement (TTM) | |
---|---|
Revenue | ₹459.39m |
Cost of Revenue | ₹87.40m |
Gross Profit | ₹371.99m |
Other Expenses | ₹347.48m |
Earnings | ₹24.51m |
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
Aug 09, 2022
Earnings per share (EPS) | 1.95 |
Gross Margin | 80.98% |
Net Profit Margin | 5.34% |
Debt/Equity Ratio | 104.3% |
How did 524202 perform over the long term?
See historical performance and comparisonValuation
Is 524202 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Analyst Forecast
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 524202?
Other financial metrics that can be useful for relative valuation.
What is 524202's n/a Ratio? | |
---|---|
n/a Ratio | 0x |
n/a | n/a |
Market Cap | ₹1.13b |
Key Statistics | |
---|---|
Enterprise Value/Revenue | 3.3x |
Enterprise Value/EBITDA | 12.5x |
PEG Ratio | n/a |
Price to Earnings Ratio vs Peers
How does 524202's PE Ratio compare to its peers?
524202 PE Ratio vs Peers |
---|
Company | PE | Estimated Growth | Market Cap |
---|---|---|---|
Peer Average | 36.1x | ||
524790 Everest Organics | 100.9x | n/a | ₹1.2b |
524506 Coral Laboratories | 9.9x | n/a | ₹898.3m |
VAISHALI Vaishali Pharma | 19.8x | n/a | ₹936.0m |
506128 Parnax Lab | 13.7x | n/a | ₹1.1b |
524202 Lactose (India) | 46x | n/a | ₹1.1b |
Price-To-Earnings vs Peers: 524202 is expensive based on its Price-To-Earnings Ratio (46x) compared to the peer average (36.1x).
Price to Earnings Ratio vs Industry
How does 524202's PE Ratio compare vs other companies in the IN Pharmaceuticals Industry?
Price-To-Earnings vs Industry: 524202 is expensive based on its Price-To-Earnings Ratio (46x) compared to the Indian Pharmaceuticals industry average (21.8x)
Price to Earnings Ratio vs Fair Ratio
What is 524202's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
Fair Ratio | |
---|---|
Current PE Ratio | 46x |
Fair PE Ratio | n/a |
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate 524202's Price-To-Earnings Fair Ratio for valuation analysis.
Share Price vs Fair Value
What is the Fair Price of 524202 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: 524202 (₹89.55) is trading above our estimate of fair value (₹81.28)
Significantly Below Fair Value: 524202 is trading above our estimate of fair value.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
Future Growth
How is Lactose (India) forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Future Growth Score
0/6Future Growth Score 0/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE
18.8%
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Lactose (India) has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Discover growth companies
- Take a look at our analysis of 524202’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
- Lactose (India) competitive advantages and company strategy can generally be found in its financial reports archived here.
Past Performance
How has Lactose (India) performed over the past 5 years?
Past Performance Score
2/6Past Performance Score 2/6
Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE
-39.2%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 524202 has high quality earnings.
Growing Profit Margin: 524202 became profitable in the past.
Past Earnings Growth Analysis
Earnings Trend: 524202's earnings have declined by 39.2% per year over the past 5 years.
Accelerating Growth: 524202 has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: 524202 has become profitable in the last year, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (2.5%).
Return on Equity
High ROE: 524202's Return on Equity (6.2%) is considered low.
Discover strong past performing companies
Financial Health
How is Lactose (India)'s financial position?
Financial Health Score
3/6Financial Health Score 3/6
Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Debt Coverage
Interest Coverage
Financial Position Analysis
Short Term Liabilities: 524202's short term assets (₹227.5M) exceed its short term liabilities (₹149.1M).
Long Term Liabilities: 524202's short term assets (₹227.5M) do not cover its long term liabilities (₹360.3M).
Debt to Equity History and Analysis
Debt Level: 524202's net debt to equity ratio (99.4%) is considered high.
Reducing Debt: 524202's debt to equity ratio has reduced from 128.8% to 104.3% over the past 5 years.
Debt Coverage: 524202's debt is well covered by operating cash flow (20.7%).
Interest Coverage: 524202's interest payments on its debt are not well covered by EBIT (1.6x coverage).
Balance Sheet
Discover healthy companies
Dividend
What is Lactose (India) current dividend yield, its reliability and sustainability?
Dividend Score
0/6Dividend Score 0/6
Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Cash Flow Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate 524202's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate 524202's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if 524202's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if 524202's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as 524202 has not reported any payouts.
Discover strong dividend paying companies
Management
How experienced are the management team and are they aligned to shareholders interests?
6.3yrs
Average management tenure
CEO
Atul Maheshwari (57 yo)
8.58yrs
Tenure
₹9,578,000
Compensation
Mr. Atul Surajmal Maheshwari, MBA, has been Independent Non–Executive Director at Photoquip India Limited since November 11, 2019. He has been Managing Director of Lactose (India) Ltd., since January 24, 2...
CEO Compensation Analysis
Compensation vs Market: Atul's total compensation ($USD120.39K) is above average for companies of similar size in the Indian market ($USD37.79K).
Compensation vs Earnings: Atul's compensation has been consistent with company performance over the past year.
Leadership Team
Experienced Management: 524202's management team is seasoned and experienced (6.3 years average tenure).
Board Members
Experienced Board: 524202's board of directors are seasoned and experienced ( 12.6 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 10.1%.
Top Shareholders
Company Information
Lactose (India) Limited's employee growth, exchange listings and data sources
Key Information
- Name: Lactose (India) Limited
- Ticker: 524202
- Exchange: BSE
- Founded: 1991
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: ₹1.127b
- Shares outstanding: 12.59m
- Website: https://www.lactoseindialimited.com
Number of Employees
Location
- Lactose (India) Limited
- Unit No. G-02
- A Wing, Ground Floor
- Mumbai
- Maharashtra
- 400015
- India
Listings
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2022/08/09 00:00 |
End of Day Share Price | 2022/08/08 00:00 |
Earnings | 2022/03/31 |
Annual Earnings | 2022/03/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.